Syensqo Reports Q1 2026 Results: Specialty Polymers and Novecare Drive Sequential Growth
Syensqo announced its first-quarter 2026 financial results on May 15, 2026, revealing a period of sequential recovery despite broader macroeconomic headwinds. While year-on-year comparisons were impacted by foreign exchange movements, the company achieved a 5% sequential increase in net sales, reaching €1.4 billion. This growth was primarily fueled by higher volumes within the Specialty Polymers and Novecare business segments.
The results underscore a stabilizing trend in volume, which helped offset the adverse effects of currency fluctuations. As the company continues its strategic evolution, management has maintained its full-year 2026 underlying EBITDA outlook while adjusting capital expenditure projections downward.
Financial Performance and Margin Expansion
Syensqo’s top-line performance for the first quarter showed resilience. Net sales reached €1.4 billion, representing a 5% increase compared to the previous quarter. This momentum was largely driven by the Specialty Polymers and Novecare divisions, even as pricing remained stable across the board.
Profitability metrics also showed significant sequential improvement:
- Gross Profit: The company reported a gross profit of €444 million, resulting in a gross margin of 31.7%. While this was down year-on-year due to foreign exchange impact and an unfavorable product mix, it represented a substantial sequential jump. Compared to the fourth quarter of 2025, gross profit rose by 15%, with the gross margin expanding by 260 basis points, a trend primarily driven by growth in Specialty Polymers.
- Underlying EBITDA: Underlying EBITDA stood at €251 million, marking a 6% increase on a sequential basis. This growth was supported by performance in Specialty Polymers, Novecare, and Composite Materials. On an organic year-on-year basis, however, underlying EBITDA decreased by 13%, resulting in an underlying EBITDA margin of 17.9%.
- Shareholder Profit: Underlying profit attributable to Syensqo shareholders was reported at €68 million.
Strategic Divestments and Cash Flow Management
A key highlight of the quarter was the successful completion of the divestment of the Oil & Gas business unit in January. This strategic move generated net proceeds of approximately €130 million, aligning with the company’s focus on high-growth, specialized material sectors.
The company’s cash position remains a focal point for investors. Operating cash flow for the quarter was €82 million, a figure that includes approximately €30 million in final payments related to separation costs. Capital expenditures were significantly reduced, totaling €97 million—a 44% decrease compared to the same period last year.
Future Outlook and Guidance
Looking ahead to the remainder of 2026, Syensqo has signaled a disciplined approach to capital allocation. The company has kept its full-year 2026 underlying EBITDA outlook unchanged. However, it has lowered its capital expenditure guidance by up to €50 million, reflecting a more conservative approach to spending as it optimizes its portfolio.
Key Takeaways for Investors
- Sequential Recovery: Net sales rose 5% and underlying EBITDA rose 6% compared to Q4 2025.
- Segment Strength: Specialty Polymers and Novecare remain the primary engines of volume growth.
- Margin Improvement: Gross margin expanded by 260 basis points sequentially.
- Portfolio Optimization: The Oil & Gas divestment is complete, providing €130 million in net proceeds.
- Updated CapEx: Full-year capital expenditure guidance has been lowered by up to €50 million.
Frequently Asked Questions
Why did net sales decrease year-on-year despite sequential growth?
The year-on-year decrease in net sales was primarily due to the adverse impact of foreign exchange movements, which offset stable overall year-on-year volumes.
Which business segments drove the recent growth?
The sequential increase in net sales and underlying EBITDA was driven largely by the Specialty Polymers and Novecare segments, with Composite Materials also contributing to EBITDA growth.
What is the status of Syensqo’s full-year 2026 guidance?
Syensqo has maintained its underlying EBITDA outlook for the full year 2026, though it has reduced its expected capital expenditure by up to €50 million.